Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging

Phase 1

• Conditions: Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).; MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2023-507482-26-00
• Lead Sponsor: nicancer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-20
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 195

Inclusion Criteria

Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent., Adequate liver function with bilirubin <3 mg/dL and albumin >2.5 g/dL., Systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg, as documented at baseline. Patients with hypertension are eligible if their hypertension is controlled and they meet all other eligibility criteria., Adequate kidney function with a creatinine clearance >30 mL/min (Cockcroft-Gault)., Patient with Eastern Cooperative Oncology group (ECOG) performance status (PS) =1., Patient is willing to use contraceptive during and for at least 1 week after discontinuing darolutamide., Patient affiliated to the social security system (or equivalent according to local regulations for participation in clinical trials)., Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up., Patients aged =18 years., Patient with histologically confirmed of adenocarcinoma prostate cancer without small cell or pure endocrine features., Patient with a history of local treatment with curative intent for localised prostate cancer, including surgery or radiotherapy., Patients with castration resistant prostate cancer,, Detection of 1 to 5 metastatic sites (pelvic lymph nodes included) on new generation PET using either choline, fluciclovine, or PSMA as tracer;, All metastatic sites must be amenable to stereotactic radiation therapy., Patient with normal haematological function: absolute neutrophil count (ANC) >1.0 x 10^9/L, platelets count =100 x 10^9/L, and haemoglobin =9.0 g/dL., Patient with normal liver function with total bilirubin =1.5 upper limit of normal (ULN) (unless documented Gilbert’s syndrome), ASAT and ALAT =2.5 ULN (=5 ULN in the presence of liver metastases).

Exclusion Criteria

Patient previously treated for metastatic prostate cancer with a novel hormonal agent (NHA), a CYP17 inhibitor, ketoconazole, chemotherapy, or immunotherapy., Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial., Person deprived of their liberty or under protective custody or guardianship., A history of cancer, other than the prostate cancer under study, within the 3 years prior to study inclusion, excluding cured localised cancer such as non-melanomatous skin cancer and non-muscle invasive bladder cancer., Presence of an uncontrolled disease or affection that according to the investigator will hinder compliance with the trial procedures or requires hospitalisation., Known to have active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease at screening, Patients with known allergy or severe hypersensitivity to the study treatment or any of its excipients., Inability and/or difficulty to swallow oral medications., Gastrointestinal disorder or procedure that can be expected to interfere significantly with the absorption of study treatment., Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV., Patients participating in another therapeutic trial within the 30 days prior to randomisation.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified